
Sun Jae Yoo
Examiner (ID: 13861, Phone: (571)272-9074 , Office: P/1626 )
| Most Active Art Unit | 1626 |
| Art Unit(s) | 1609, 1626, 1622, 1621 |
| Total Applications | 1806 |
| Issued Applications | 1149 |
| Pending Applications | 163 |
| Abandoned Applications | 560 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20452976
[patent_doc_number] => 12516026
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-06
[patent_title] => Cabozantinib compositions and methods of use
[patent_app_type] => utility
[patent_app_number] => 19/265483
[patent_app_country] => US
[patent_app_date] => 2025-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 15
[patent_no_of_words] => 30321
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19265483
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/265483 | Cabozantinib compositions and methods of use | Jul 9, 2025 | Issued |
Array
(
[id] => 20452976
[patent_doc_number] => 12516026
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-06
[patent_title] => Cabozantinib compositions and methods of use
[patent_app_type] => utility
[patent_app_number] => 19/265483
[patent_app_country] => US
[patent_app_date] => 2025-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 15
[patent_no_of_words] => 30321
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19265483
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/265483 | Cabozantinib compositions and methods of use | Jul 9, 2025 | Issued |
Array
(
[id] => 20136122
[patent_doc_number] => 20250243166
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-31
[patent_title] => CABOZANTINIB COMPOSITIONS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 19/184689
[patent_app_country] => US
[patent_app_date] => 2025-04-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30294
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 191
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19184689
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/184689 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | Apr 20, 2025 | Pending |
Array
(
[id] => 20150400
[patent_doc_number] => 20250250238
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-08-07
[patent_title] => CABOZANTINIB COMPOSITIONS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 19/184838
[patent_app_country] => US
[patent_app_date] => 2025-04-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30861
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 158
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19184838
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/184838 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | Apr 20, 2025 | Issued |
Array
(
[id] => 20164990
[patent_doc_number] => 20250257036
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-08-14
[patent_title] => CABOZANTINIB COMPOSITIONS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 19/184766
[patent_app_country] => US
[patent_app_date] => 2025-04-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30964
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 150
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19184766
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/184766 | Cabozantinib compositions and methods of use | Apr 20, 2025 | Issued |
Array
(
[id] => 20150400
[patent_doc_number] => 20250250238
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-08-07
[patent_title] => CABOZANTINIB COMPOSITIONS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 19/184838
[patent_app_country] => US
[patent_app_date] => 2025-04-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30861
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 158
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19184838
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/184838 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | Apr 20, 2025 | Issued |
Array
(
[id] => 19983958
[patent_doc_number] => 20250122180
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-17
[patent_title] => DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/999866
[patent_app_country] => US
[patent_app_date] => 2024-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5395
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18999866
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/999866 | DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF | Dec 22, 2024 | Pending |
Array
(
[id] => 19983958
[patent_doc_number] => 20250122180
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-17
[patent_title] => DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/999866
[patent_app_country] => US
[patent_app_date] => 2024-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5395
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18999866
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/999866 | DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF | Dec 22, 2024 | Pending |
Array
(
[id] => 20227141
[patent_doc_number] => 12415784
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-16
[patent_title] => Cabozantinib compositions and methods of use
[patent_app_type] => utility
[patent_app_number] => 18/938926
[patent_app_country] => US
[patent_app_date] => 2024-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 15
[patent_no_of_words] => 31006
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18938926
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/938926 | Cabozantinib compositions and methods of use | Nov 5, 2024 | Issued |
Array
(
[id] => 19707795
[patent_doc_number] => 20250017937
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-16
[patent_title] => MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES
[patent_app_type] => utility
[patent_app_number] => 18/779430
[patent_app_country] => US
[patent_app_date] => 2024-07-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7468
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18779430
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/779430 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES | Jul 21, 2024 | Pending |
Array
(
[id] => 19707795
[patent_doc_number] => 20250017937
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-16
[patent_title] => MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES
[patent_app_type] => utility
[patent_app_number] => 18/779430
[patent_app_country] => US
[patent_app_date] => 2024-07-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7468
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18779430
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/779430 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES | Jul 21, 2024 | Pending |
Array
(
[id] => 19584955
[patent_doc_number] => 20240382512
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-21
[patent_title] => Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
[patent_app_type] => utility
[patent_app_number] => 18/771270
[patent_app_country] => US
[patent_app_date] => 2024-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31398
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18771270
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/771270 | Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof | Jul 11, 2024 | Pending |
Array
(
[id] => 19403497
[patent_doc_number] => 20240287008
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => METHOD FOR THE SYNTHESIS OF 3-R-1,4,2-DIOXAZOL-5-ONES
[patent_app_type] => utility
[patent_app_number] => 18/643948
[patent_app_country] => US
[patent_app_date] => 2024-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6985
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18643948
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/643948 | METHOD FOR THE SYNTHESIS OF 3-R-1,4,2-DIOXAZOL-5-ONES | Apr 22, 2024 | Pending |
Array
(
[id] => 19543104
[patent_doc_number] => 20240360140
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/620225
[patent_app_country] => US
[patent_app_date] => 2024-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63322
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -41
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18620225
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/620225 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | Mar 27, 2024 | Pending |
Array
(
[id] => 20256058
[patent_doc_number] => 12428401
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-30
[patent_title] => Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
[patent_app_type] => utility
[patent_app_number] => 18/618379
[patent_app_country] => US
[patent_app_date] => 2024-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 14
[patent_no_of_words] => 3057
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18618379
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/618379 | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | Mar 26, 2024 | Issued |
Array
(
[id] => 20256058
[patent_doc_number] => 12428401
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-30
[patent_title] => Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
[patent_app_type] => utility
[patent_app_number] => 18/618379
[patent_app_country] => US
[patent_app_date] => 2024-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 14
[patent_no_of_words] => 3057
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18618379
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/618379 | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | Mar 26, 2024 | Issued |
Array
(
[id] => 20156951
[patent_doc_number] => 12383549
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-12
[patent_title] => Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
[patent_app_type] => utility
[patent_app_number] => 18/617723
[patent_app_country] => US
[patent_app_date] => 2024-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4329
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18617723
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/617723 | Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders | Mar 26, 2024 | Issued |
Array
(
[id] => 20156951
[patent_doc_number] => 12383549
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-12
[patent_title] => Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
[patent_app_type] => utility
[patent_app_number] => 18/617723
[patent_app_country] => US
[patent_app_date] => 2024-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4329
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18617723
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/617723 | Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders | Mar 26, 2024 | Issued |
Array
(
[id] => 20256058
[patent_doc_number] => 12428401
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-30
[patent_title] => Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
[patent_app_type] => utility
[patent_app_number] => 18/618379
[patent_app_country] => US
[patent_app_date] => 2024-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 14
[patent_no_of_words] => 3057
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18618379
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/618379 | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | Mar 26, 2024 | Issued |
Array
(
[id] => 19554793
[patent_doc_number] => 20240366585
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (RMS)
[patent_app_type] => utility
[patent_app_number] => 18/613641
[patent_app_country] => US
[patent_app_date] => 2024-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42499
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18613641
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/613641 | Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (RMS) | Mar 21, 2024 | Pending |